RxDoctor Payments Data

Shannon Carlson

Acute Care · Springfield, ORNPI 1700285582

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Johnson & Johnson at 24.9% of the total.

$1,147in general payments, 2019–2025

Across 18 payments — averaging $63.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$285
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$212
  • Abbott$129
  • Atricure, Inc.$127
  • Sanofi-aventis U.S. LLC$114
  • Alnylam Pharmaceuticals Inc.$98
  • plus $183 from 3 others

What the payments were for

  • Food & beverage$1,147100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,147 in reported general payments places this provider in the 75th percentile of 105 acute care providers in Oregon.

See all acute care providers in Oregon

Medicare billing

Part B allowed, 2024
$27,303
Medicare patients
282
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban204$247,695
JardianceEmpagliflozin85$91,444
Repatha SureclickEvolocumab113$81,761
EntrestoSacubitril/Valsartan52$57,821
FarxigaDapagliflozin Propanediol40$26,630
XareltoRivaroxaban16$21,651
Praluent PenAlirocumab15$15,920
Metoprolol Succinate293$4,759
Rosuvastatin Calcium168$2,780
Ezetimibe89$2,140
Isosorbide Mononitrate ErIsosorbide Mononitrate115$1,777
Nitroglycerin129$1,460
Atorvastatin Calcium124$1,451
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$1,190
Flecainide Acetate27$1,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$285$21,65116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 105 acute care providers in Oregon.

Other acute care in Springfield

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →